Lipid mediators in diabetic nephropathy

Table 1 Effect of lipid lowering drugs on the renal outcome

Drugs	Effect on renal outcome	References
Statins and Fenofibrate	Reduction in urinary albumin	[3, 4]
Atorvastatins with combine therapy with glycaemic control	Inhibit cardiovascular and renal end points by 50% in DN patients	[46]
Pitavastatin and Pravastatin	Reduction in urinary albumin in DN patients	[44]
Pitavastatin and Pravastatin	Pitavastatin is more effective than Pravastatin	[44]
Rosuvastatin	Reduction in albuminuria, oxidative stress, and serum cystatin C levels in DN patients	[45]
Atorvastatin	Not remarkable difference in renal functions between those taking high or low dose atorvastatin over 2 years	[46]
Atorvastatin	Atorvastatin was effective at decreasing CVD in those with and without a moderately decreased eGFR	[47]
Fenofibrate	Not remarkable difference in GFR, Provide reno-protection in moderate renal impairment patients	[56, 58]
Fenofibrate	Inhibit risk of albuminuria in patient with diabetes	[59]
Fenofibrate	Acute change in creatinine not associated with adverse effect on renal outcome	[56, 57]
Simvastatin (and simvastatin + ezetimibe)	Does not produce remarkable reductions in measures of renal disease progression	[61–63]

ISSN: 1755-1536